INTERIM SVR12 RESULTS FROM THE TELAPREVIR PHASE 3B REPLACE STUDY IN TREATMENT-NAIVE STABLE LIVER TRANSPLANT PATIENTS WITH GENOTYPE 1 HCV INFECTION

被引：0

作者：

Forns, X. ^{[1
,2
]}

Samuel, D. ^{[3
]}

Mutimer, D. ^{[4
,5
]}

Fagiouli, S. ^{[6
]}

Navasa, M. ^{[7
]}

Agarwal, K. ^{[8
]}

Berenguer, M. ^{[9
,10
]}

Colombo, M. ^{[11
]}

Herzer, K. ^{[12
]}

Nevens, F. ^{[13
]}

Van Solingen-Ristea, R. ^{[14
]}

Luo, D. ^{[14
]}

Dierynck, I. ^{[15
]}

Witek, J. ^{[15
]}

机构：

[1] CIBEREHD, Liver Unit, Hosp Clin, Barcelona, Spain

[2] IDIBAPS, Barcelona, Spain

[3] Univ Paris South Villejuif, Hosp Paul Brousse, Ctr Hepatobiliaire, Paris, France

[4] Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England

[5] NIHR BRU, Birmingham, W Midlands, England

[6] Papa Giovanni XXIII Hosp, Gastroenterol & Transplant Hepatol, Bergamo, Italy

[7] Hosp Clin Barcelona, Liver Unit, Barcelona, Spain

[8] Kings Coll Hosp London, London, England

[9] Hosp La Fe, E-46009 Valencia, Spain

[10] CIBEREHD, Valencia, Spain

[11] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy

[12] Univ Hosp Essen, Liver Transplantat Unit, Essen, Germany

[13] Univ Hosp KU Leuven, Leuven, Belgium

[14] Janssen Res & Dev LLC, Titusville, NJ USA

[15] Janssen Infect Dis BVBA, Beerse, Belgium

来源：

JOURNAL OF HEPATOLOGY | 2014年 / 60卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P1185

引用

页码：S481 / S481

页数：1

共 50 条

[41] SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAIVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL
Jacobson, I.
Dore, G. J.
Foster, G. R.
Fried, M. W.
Radu, M.
Rafalskiy, V. V.
Moroz, L.
Craxi, A.
Peeters, M.
Lenz, O.
Ouwerkerk-Mahadevan, S.
Kalmeijer, R.
Beumont-Mauviel, M.
JOURNAL OF HEPATOLOGY, 2013, 58 : S574 - S574
[42] A Bayesian Bridging Model Using Phase 3 Data in Treatment-Experienced HCV Genotype 3 Patients Demonstrates Extending Sofosbuvir plus Ribavirin Treatment from 12 to 16 Weeks in Treatment-Naive Genotype 3 Patients May Significantly Increase SVR Rates
Bekele, B. Nebiyou
Nelson, David R.
Gordon, Stuart C.
Feld, Jordan J.
Patel, Keyur
Lawitz, Eric
Sheikh, Aasim M.
Brainard, Diana M.
Symonds, William T.
McHutchison, John G.
Mangia, Alessandra
Gane, Edward J.
HEPATOLOGY, 2013, 58 : 754A - 754A
[43] Interim sustained virologic response (SVR), safety and tolerability results of 8-week treatment with ACH-3102 and sofosbuvir in chronic hepatitis C (HCV), genotype-1 (GT-1), treatment-naive patients: a Phase 2 "proxy" study
Gane, Edward J.
Kocinsky, Hetal
Schwabe, Christian
Mader, Michael
Suri, Vithika
Donohue, Mary K.
Huang, Mingjun
Hui, James
Yang, Joanna
Apelian, David
HEPATOLOGY, 2014, 60 (06) : 1281A - 1282A
[44] TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA2A AND RIBAVIRIN FOR 24 OR 48 WEEKS IN TREATMENT-NAiVE GENOTYPE 1 HCV PATIENTS WHO ACHIEVED AN EXTENDED RAPID VIRAL RESPONSE: FINAL RESULTS OF PHASE 3 ILLUMINATE STUDY
Sherman, Kenneth E.
Flamm, Steven L.
Afdhal, Nezam H.
Nelson, David R.
Sulkowski, Mark S.
Everson, Gregory T.
Fried, Michael W.
Kleber, Kristin
Martins, Marie
Sankoh, Abdul J.
Kauffman, Robert S.
George, Shelley
Wright, Christopher I.
Poordad, Fred
HEPATOLOGY, 2010, 52 (04) : 401A - 402A
[45] RESULTS OF A PROOF OF CONCEPT STUDY (C210) OF TELAPREVIR MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 4 HCV PATIENTS
Benhamou, Y.
Moussalli, J.
Ratziu, V.
Lebray, P.
Gysen, V.
de Backer, K.
Ghys, A.
van Heeswijk, R.
Vangeneugden, I.
Picchio, G.
Beumont-Mauviel, M.
JOURNAL OF HEPATOLOGY, 2009, 50 : S6 - S6
[46] A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus
Ahn, S. H.
Lim, Y. S.
Lee, K. S.
Paik, S. W.
Lee, Y. J.
Jeong, S. H.
Kim, J. H.
Yoon, S. K.
Yim, H. J.
Tak, W. Y.
Han, S. Y.
Yang, J. C.
Mo, H.
Mathias, A.
Han, L.
Knox, S. J.
Brainard, D. M.
Kim, Y. J.
Byun, K. S.
Kim, Y. S.
Heo, J.
Han, K. H.
JOURNAL OF VIRAL HEPATITIS, 2016, 23 (05) : 358 - 365
[47] Simeprevir (TMC435) With Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype-1 Infection in Treatment-Naive Patients: Results From QUEST-2, a Phase III Trial
Poordad, Fred
Manns, Michael P.
Marcellin, Patrick
de Araujo, Evaldo Stanislau Affonso
Buti, Maria
Horsmans, Yves
Janczewska, Ewa
Villamil, Federico
Peeters, Monika
Lenz, Oliver
Ouwerkerk-Mahadevan, Sivi
Kalmeijer, Ronald
Beumont-Mauviel, Maria
GASTROENTEROLOGY, 2013, 144 (05) : S151 - S151
[48] SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAIVE PATIENTS: RESULTS FROM QUEST-2, A PHASE III TRIAL
Manns, M.
Marcellin, P.
Poordad, F. P. Fred
Stanislau Affonso de Araujo, E.
Buti, M.
Horsmans, Y.
Janczewska, E. J. Ewa
Villamil, F.
Peeters, M.
Lenz, O.
Ouwerkerk-Mahadevan, S.
Kalmeijer, R.
Beumont-Mauviel, M.
JOURNAL OF HEPATOLOGY, 2013, 58 : S568 - S568
[49] ACTIVITY OF TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 2 AND 3 HEPATITIS-C PATIENTS: INTERIM RESULTS OF STUDY C209
Foster, G. R.
Hezode, C.
Bronowicki, J. -P.
Carosi, G.
Weiland, O.
Verlinden, L.
van Heeswijk, R.
Vangeneugden, T.
Picchio, G.
Beumont-Mauviel, M.
JOURNAL OF HEPATOLOGY, 2009, 50 : S22 - S22
[50] HCVerso1: A phase III study of faldaprevir (FDV) plus deleobuvir (DBV) and ribavirin (RBV) for chronic HCV genotype (GT)-1b infection in treatment-naive patients
Sarrazin, Christoph
Castelli, Francesco
Puoti, Massimo
Shiffman, Mitchell L.
Preotescu, Liliana
Forns, Xavier
Buti, Maria
Yoshida, Eric M.
Bourliere, Marc
Oliveira, Celia
Stern, Jerry O.
Boecher, Wulf O.
Kukolj, George
Haefner, Carla
Vinisko, Richard
Garcia, Miguel
Mensa, Federico J.
HEPATOLOGY, 2014, 60 : 1150A - 1150A

← 1 2 3 4 5 →